Matches in SemOpenAlex for { <https://semopenalex.org/work/W4281646670> ?p ?o ?g. }
Showing items 1 to 73 of
73
with 100 items per page.
- W4281646670 abstract "Background: Existing observational studies yielded mixed results between cognitive and dementia outcomes and newer glucose-lowering drugs (GLDs) , i.e., dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 receptor agonists (GLP-1RAs) , and sodium-glucose co-transporter-2 (SGLT2) inhibitors, while individual randomized trials have inadequate power to examine such an effect. Thus, we aimed to evaluate the effect of these newer GLDs on the risk of dementia by performing a meta-analysis of randomized outcome trials. Methods: We included published randomized placebo-controlled cardiovascular and renal outcome trials that evaluated DPP-4 inhibitors, GLP-1RAs, and SGLT2 inhibitors and reported dementia events. The study outcomes were all-cause dementia and vascular dementia, extracted from clinicaltrials.gov. We calculated pooled odds ratios (OR) and 95% CIs using the Peto method. Results: We included 21 trials involving 1all-cause dementia cases (including 22 vascular dementia cases) among 167,5patients with or without type 2 diabetes over a median follow-up of 2.2 years. Neither DPP-4 inhibitors (OR, 0.65 [0.33-1.29]) , GLP-1RAs (OR, 0.88 [0.51-1.52]) , or SGLT2 inhibitors (OR, 1.22 [0.54-2.74]) were significantly associated with all-cause dementia incidence. For vascular dementia, compared with placebo, SGLT2 inhibitors were significantly associated with a decreased risk (OR, 0.[0.02-0.66]) , while DPP-4 inhibitors (OR, 0.67 [0.12-3.85]) and GLP-1RAs (OR, 0.37 [0.12-1.14]) did not significantly decrease the risk. No evidence of statistical heterogeneity or publication bias was detected in the meta-analysis (p >0.05) . Conclusion: SGLT2 inhibitors may have a beneficial effect on lowering the vascular dementia risk, thus may be a drug repurposing signal. Nevertheless, future randomized controlled trials and/or comparative effectiveness studies using real-world data are warranted to further confirm our conclusion. Disclosure H.Tang: None. S.Niu: None. J.D.Brown: None. J.Wei: None. A.G.Winterstein: Consultant; Genentech, Inc., Research Support; Merck & Co., Inc. J.Bian: None. J.Guo: None." @default.
- W4281646670 created "2022-06-13" @default.
- W4281646670 creator A5005377764 @default.
- W4281646670 creator A5006457953 @default.
- W4281646670 creator A5012913975 @default.
- W4281646670 creator A5013122645 @default.
- W4281646670 creator A5051850406 @default.
- W4281646670 creator A5063222052 @default.
- W4281646670 creator A5069237540 @default.
- W4281646670 date "2022-06-01" @default.
- W4281646670 modified "2023-09-30" @default.
- W4281646670 title "870-P: Newer Glucose-Lowering Drugs and Risk of Dementia: A Meta-analysis of Cardiovascular Outcome Trials" @default.
- W4281646670 doi "https://doi.org/10.2337/db22-870-p" @default.
- W4281646670 hasPublicationYear "2022" @default.
- W4281646670 type Work @default.
- W4281646670 citedByCount "1" @default.
- W4281646670 countsByYear W42816466702022 @default.
- W4281646670 crossrefType "journal-article" @default.
- W4281646670 hasAuthorship W4281646670A5005377764 @default.
- W4281646670 hasAuthorship W4281646670A5006457953 @default.
- W4281646670 hasAuthorship W4281646670A5012913975 @default.
- W4281646670 hasAuthorship W4281646670A5013122645 @default.
- W4281646670 hasAuthorship W4281646670A5051850406 @default.
- W4281646670 hasAuthorship W4281646670A5063222052 @default.
- W4281646670 hasAuthorship W4281646670A5069237540 @default.
- W4281646670 hasConcept C126322002 @default.
- W4281646670 hasConcept C134018914 @default.
- W4281646670 hasConcept C142724271 @default.
- W4281646670 hasConcept C156490143 @default.
- W4281646670 hasConcept C156957248 @default.
- W4281646670 hasConcept C168563851 @default.
- W4281646670 hasConcept C204787440 @default.
- W4281646670 hasConcept C27081682 @default.
- W4281646670 hasConcept C2777180221 @default.
- W4281646670 hasConcept C2777952318 @default.
- W4281646670 hasConcept C2779134260 @default.
- W4281646670 hasConcept C2779483572 @default.
- W4281646670 hasConcept C555293320 @default.
- W4281646670 hasConcept C71924100 @default.
- W4281646670 hasConcept C95190672 @default.
- W4281646670 hasConceptScore W4281646670C126322002 @default.
- W4281646670 hasConceptScore W4281646670C134018914 @default.
- W4281646670 hasConceptScore W4281646670C142724271 @default.
- W4281646670 hasConceptScore W4281646670C156490143 @default.
- W4281646670 hasConceptScore W4281646670C156957248 @default.
- W4281646670 hasConceptScore W4281646670C168563851 @default.
- W4281646670 hasConceptScore W4281646670C204787440 @default.
- W4281646670 hasConceptScore W4281646670C27081682 @default.
- W4281646670 hasConceptScore W4281646670C2777180221 @default.
- W4281646670 hasConceptScore W4281646670C2777952318 @default.
- W4281646670 hasConceptScore W4281646670C2779134260 @default.
- W4281646670 hasConceptScore W4281646670C2779483572 @default.
- W4281646670 hasConceptScore W4281646670C555293320 @default.
- W4281646670 hasConceptScore W4281646670C71924100 @default.
- W4281646670 hasConceptScore W4281646670C95190672 @default.
- W4281646670 hasIssue "Supplement_1" @default.
- W4281646670 hasLocation W42816466701 @default.
- W4281646670 hasOpenAccess W4281646670 @default.
- W4281646670 hasPrimaryLocation W42816466701 @default.
- W4281646670 hasRelatedWork W1981859602 @default.
- W4281646670 hasRelatedWork W2081526989 @default.
- W4281646670 hasRelatedWork W2171933770 @default.
- W4281646670 hasRelatedWork W2187765733 @default.
- W4281646670 hasRelatedWork W2188891384 @default.
- W4281646670 hasRelatedWork W2783359685 @default.
- W4281646670 hasRelatedWork W3118154807 @default.
- W4281646670 hasRelatedWork W3215457371 @default.
- W4281646670 hasRelatedWork W4229451599 @default.
- W4281646670 hasRelatedWork W4300970712 @default.
- W4281646670 hasVolume "71" @default.
- W4281646670 isParatext "false" @default.
- W4281646670 isRetracted "false" @default.
- W4281646670 workType "article" @default.